The site uses anonymous third party analytic cookies: in accessing any element/area of the site outside of this banner, you consent to receiving cookies.

CCG mergers drive integrated care agenda

Oli Hudson, of Wilmington Healthcare, assesses the latest tranche of Clinical Commissioning Group (CCG) mergers and what they mean for industry...

New rules of engagement

Healthcare systems have changed forever as a result of Covid-19 Simon Grime, of Wilmington Healthcare, examines how pharma should respond to the new...

[Download] Coronavirus and cancer services: Exploring the impact of covid-19

What impact will covid-19 have on the delivery of cancer services Prior to the outbreak of the coronavirus pandemic, the Long-term Plan set out...

COVID-19 and the critical role of MedTech

COVID-19 is changing the face of healthcare at an unprecedented pace We examine the key role MedTech has in tackling the virus, how to tackle some of...

Delivering true value: what does it mean for KAM in cancer care?

Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the...

Value-based procurement: could it become a reality?

Oli Hudson, content director at Wilmington Healthcare, looks at value-based procurement and its place in procurement in the emerging NHS...

[Download] Looking Ahead: The NHS in 2020

Welcome to Wilmington Healthcare’s Looking Ahead: The NHS in 2020, where we take a look at some of the big themes emerging in the NHS this year and...

[Animation] Impact of diagnostic staging in cancer

The Long-term Plan has set ambitious targets to improve earlier stage diagnosis in cancer The NHS has identified a group of clinical priorities,...

Mapping the intricate oncology landscape

Simon Grime, of Wilmington Healthcare, explains how data and intelligence tools help pharma deliver tailored engagement programmes to diverse...

GIRFT: Can ophthalmology point to where other NHS areas are heading?

Oli Hudson, Content Director at Wilmington Healthcare, looks at the latest GIRFT report and sees what lessons it holds for the MedTech industry at...

What next for biosimilars?

James Roach, Director at West Essex ICP, looks at the future for biosimilar medicines, surveys a future landscape where medicines management will be...

Latest Tweets from @Wilmhealthcare